CliffBio
small molecule

KETOROLAC TROMETHAMINE

KETOROLAC TROMETHAMINE

Loss of exclusivity—loss of exclusivity
CompanyAmphastar Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameKETOROLAC TROMETHAMINE
Active ingredientKETOROLAC TROMETHAMINE
Strength15MG/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJuly 2004
Marketing statusDISCN

More from Amphastar Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

KETOROLAC TROMETHAMINE patent cliff — loss of exclusivity — | CliffBio